Compare Stocks: AMPH, OGN, TARS, and ARQT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.62 -0.8%	$21.29	$16.65 ▼ $29.52	$1.01B	0.92	384,428 shs	1.45 million shs
ARQT Arcutis Biotherapeutics	$25.34 -4.2%	$25.86	$16.57 ▼ $31.77	$3.33B	1.5	2.23 million shs	19.14 million shs
OGN Organon & Co.	$13.69 0.0%	$13.65	$5.69 ▼ $13.78	$3.60B	1.52	2.95 million shs	4.94 million shs
TARS Tarsus Pharmaceuticals	$78.09 -1.2%	$69.42	$53.85 ▼ $91.53	$3.47B	0.54	747,573 shs	710,965 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.84%	-0.67%	+8.65%	+25.57%	-12.45%
ARQT Arcutis Biotherapeutics	-4.22%	+6.09%	-4.22%	-3.30%	+47.86%
OGN Organon & Co.	0.00%	+0.29%	-0.36%	+1.86%	+30.96%
TARS Tarsus Pharmaceuticals	-1.19%	-1.54%	+6.33%	+23.64%	+51.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.62 -0.8%	$21.29	$16.65 ▼ $29.52	$1.01B	0.92	384,428 shs	1.45 million shs
ARQT Arcutis Biotherapeutics	$25.34 -4.2%	$25.86	$16.57 ▼ $31.77	$3.33B	1.5	2.23 million shs	19.14 million shs
OGN Organon & Co.	$13.69 0.0%	$13.65	$5.69 ▼ $13.78	$3.60B	1.52	2.95 million shs	4.94 million shs
TARS Tarsus Pharmaceuticals	$78.09 -1.2%	$69.42	$53.85 ▼ $91.53	$3.47B	0.54	747,573 shs	710,965 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.84%	-0.67%	+8.65%	+25.57%	-12.45%
ARQT Arcutis Biotherapeutics	-4.22%	+6.09%	-4.22%	-3.30%	+47.86%
OGN Organon & Co.	0.00%	+0.29%	-0.36%	+1.86%	+30.96%
TARS Tarsus Pharmaceuticals	-1.19%	-1.54%	+6.33%	+23.64%	+51.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-4.74% Downside
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	40.35% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-16.70% Downside
TARS Tarsus Pharmaceuticals	2.80	Moderate Buy	$94.00	20.37% Upside

Current Analyst Ratings Breakdown

Latest AMPH, OGN, TARS, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
8/6/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.40	$4.22 per share	5.60	$17.17 per share	1.38
ARQT Arcutis Biotherapeutics	$376.07M	8.47	N/A	N/A	$1.55 per share	16.35
OGN Organon & Co.	$6.22B	0.58	$5.80 per share	2.36	$2.89 per share	4.74
TARS Tarsus Pharmaceuticals	$451.36M	7.59	N/A	N/A	$8.09 per share	9.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	13.98	9.12	4.59	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	120.69	22.23	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.77	3.98	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	137.00	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest AMPH, OGN, TARS, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest AMPH, OGN, TARS, and ARQT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARQT Arcutis Biotherapeutics	N/A
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
ARQT Arcutis Biotherapeutics	9.40%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

AMPH, OGN, TARS, and ARQT Headlines

Recent News About These Companies

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

September 19 at 5:59 AM | finance.yahoo.com

Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares

September 18 at 10:45 PM | kalkinemedia.comK

Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating

September 18 at 5:59 AM | marketbeat.com

William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 17 at 5:07 PM | marketbeat.com

Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 11, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock

September 10, 2026 | insidertrades.com

Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS

September 10, 2026 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 10, 2026 | americanbankingnews.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts

September 10, 2026 | marketbeat.com

Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

September 9, 2026 | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock

September 9, 2026 | marketbeat.com

Jefferies Financial Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $105.00

September 8, 2026 | marketbeat.com

Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline

September 8, 2026 | visionmonday.comV

Legal & General Group Plc Makes New $1.75 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

September 7, 2026 | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Jefferies Financial Group

September 5, 2026 | marketbeat.com

Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition

September 4, 2026 | marketscreener.comM

Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

September 4, 2026 | finance.yahoo.com

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

September 4, 2026 | rttnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Should You Buy?

September 4, 2026 | marketbeat.com

Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline

September 4, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMPH, OGN, TARS, and ARQT Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.62 -0.20 (-0.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$23.62 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Arcutis Biotherapeutics NASDAQ:ARQT

$25.34 -1.12 (-4.22%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$25.50 +0.16 (+0.62%)

As of 09/18/2026 07:40 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Organon & Co. NYSE:OGN

$13.68 -0.01 (-0.04%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$13.68 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals NASDAQ:TARS

$78.09 -0.94 (-1.19%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$78.06 -0.03 (-0.03%)

As of 09/18/2026 07:30 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMPH, OGN, TARS, and ARQT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMPH, OGN, TARS, and ARQT Earnings

Compare Dividends

Latest AMPH, OGN, TARS, and ARQT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMPH, OGN, TARS, and ARQT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMPH, OGN, TARS, and ARQT Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Arcutis Biotherapeutics NASDAQ:ARQT

Organon & Co. NYSE:OGN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools